Tissue inhibitor of metalloproteinase-3 expression affects clinicopathological features and prognosis of aflatoxin B1-related hepatocellular carcinoma

Table 7 Mulvariable Cox proportional hazard regression analysis for survival

	OS		RFS
Variable	HR (95%CI)	P value	HR (95%CI)	P value
AFP, positive vs negative	2.85 (1.96-4.15)	5.06 × 10-8	2.48 (1.64-3.73)	1.44 × 10-5
AFB1 exposure, high vs low	2.92 (1.99-4.27)	3.71 × 10-8	3.23 (2.12-4.94)	5.78 × 10-8
Tumor size (cm), > 5 vs ≤ 5	2.93 (1.99-4.31)	4.53 × 10-8	2.79 (1.83-4.25)	2.00 × 10-6
ES grade, III-IV vs I-II	1.81 (1.29-2.55)	6.19 × 10-4	1.63 (1.12-2.37)	0.01
TNM stage, II vs I	1.61 (1.02-2.42)	0.03	1.75 (1.04-2.45)	0.02
TNM stage, III vs I	6.22 (3.70-10.48)	6.21 × 10-12	4.43 (2.54-7.71)	1.47 × 10-7
MVD, positive vs negative	2.88 (2.05-4.04)	1.07 × 10-9	3.34 (2.29-4.89)	4.71 × 10-10
PVTT, positive vs negative	2.30 (1.59-3.32)	8.73 × 10-6	2.34 (1.60-3.42)	1.16 × 10-5
MVI, positive vs negative	2.48 (1.74-3.54)	5.63 × 10-7	2.44 (1.68-3.53)	2.42 × 10-6
TIMP3, LTE vs HTE	2.85 (2.04-4.00)	1.17 × 10-9	2.26 (1.57-3.26)	1.26 × 10-5

OS: Overall survival; HR: Hazard ratio; RFS: Recurrence-free survival; CI: Confidential interval; AFP: Alpha fetoprotein; AFB1: Aflatoxin B1; ES: Edmondson and Steiner; TNM: Tumor node metastasis; MVD: Microvessel density; PVTT: Portal vein tumor thrombus; MVI: Microvessel infiltration; LTE: Low TIMP3 expression; HTE: High TIMP3 expression.